KWKatherine C. Wai

Katherine C. Wai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katherine C. Wai has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Obesity and Pathologic Response to Neoadjuvant Immunotherapy in Head and Neck Cancer: Preliminary Results From a Pilot Study

    by Angeline A. Truong, Laura Chen, Rex H. Lee, Xin Wu, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, Ilya Likhterov, Michael Chow, et al.

    Objective: To evaluate associations between obesity and pathologic response to neoadjuvant immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC). Methods: This was a retrospective cohort study conducted at a single tertiary academic center. We identified 42 patients with HNSCC treated with neoadjuvant ICI with or without chemotherapy. Obesity was defined as body mass index (BMI) ≥ 30 kg/m 2 . The primary outcome was any pathologic response (partial, major, or complete response). Multivariable logistic regression was performed to assess associations between obesity and response, adjusting for smoking status and Eastern Cooperative Oncology Group (ECOG) performance status. BMI was also analyzed as a continuous variable. Adjusted predicted probabilities of response were estimated across BMI. Results: Seven patients (17%) were obese. Obese patients had lower rates of pathologic response compared to non‐obese patients (29% vs. 69%). On multivariable analysis, obesity was associated with decreased odds of response (OR 0.10, 95% CI 0.02–0.72; p = 0.021). Increasing BMI was independently associated with lower odds of response, with a 15% decrease per 1 kg/m 2 increase [OR 0.85 (0.72–0.99), p = 0.039]. Adjusted predicted probability of response declined from ~85% at BMI 18 to 25% at BMI 40. In a subset of patients receiving immunotherapy alone, increasing BMI remained associated with decreased response [OR 0.66 (0.44–0.99), p = 0.045]. Conclusion: In a small pilot cohort, obesity was associated with decreased pathologic response to neoadjuvant ICI in HNSCC. These findings contrast with the “obesity paradox” observed in recurrent/metastatic settings and suggest the relationship between metabolic state and immunotherapy response may be context‐dependent. Further validation in larger cohorts is needed. Level of Evidence: III.

  • Statin Use Is Associated With Progression‐Free Survival for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab

    by Angeline A. Truong, Savinnie Ho, Rex H. Lee, Xin Wu, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, Ilya Likhterov, Mary Jue Xu, et al.

    Background: Statins may modulate immune function and enhance immunotherapy response. This study evaluated the relationship between statin use and outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving pembrolizumab. Methods: A retrospective observational study was conducted at UCSF including patients with oral cavity, oropharyngeal, hypopharyngeal, laryngeal, or cutaneous HNSCC treated with pembrolizumab from 2016 to 2022. Primary outcome was 6‐month progression‐free survival (PFS); secondary was 2‐year overall survival (OS). Results: Among 165 patients, 60 (36%) used statins. After adjustment for ECOG status, concurrent systemic therapy, and tumor site, any statin use (HR 0.49, p = 0.012), high‐intensity statins (HR 0.46, p = 0.012), and lipophilic statin use (HR 0.54, p = 0.041) were associated with improved 6‐month PFS. Conclusions: Statin use, particularly high‐intensity regimens, was associated with improved short‐term outcomes on pembrolizumab in HNSCC. Prospective studies are warranted to elucidate underlying mechanisms.

  • Open Access

    Outcomes of Mandible Reconstruction Using Surgeon‐Specific, Patient‐Specific, and Conventional Plates

    by Nina Patel, Autefeh Sajjadi, Andrea Park, Rahul Seth, Chase Heaton, Mary Jue Xu, Katherine Wai, Ilya Likhterov, P. Daniel Knott

    Objective: To compare operative metrics, postoperative complications, and radiographic osseous union among surgeon‐specific plates (SSPs), patient‐specific plates (PSPs), and conventional un‐bent plates (CPs) in microvascular mandibular reconstruction. Methods: A retrospective review was performed of 171 patients who underwent osseous mandibular free flap reconstruction from January 2020–January 2025. Patients were stratified by plating technique: SSP ( n = 52), PSP with computer‐aided design/manufacture (CAD/CAM) ( n = 58), and CP ( n = 61). Primary outcomes included operative time, hospital length of stay, and postoperative complications. Secondary outcomes included osteotomy characteristics, CT‐based radiographic osseous union, and time‐to‐Grade 2 union. Multivariate analysis evaluated factors associated with nonunion. Results: Baseline demographics, defect characteristics, and radiation exposure were comparable across cohorts. Secondary reconstruction procedures were more frequent in the SSP cohort compared with the PSP cohort ( p = 0.05), and SSPs were more commonly used in complete (angle to angle) mandibular reconstructions. Operative time, hospital length of stay, and ischemia time did not differ significantly by plating method. Postoperative complication rates were low and similar across groups, with no significant differences in infection, hematoma, or reoperation; however, low event rates may have limited power to detect small but clinically meaningful differences between cohorts. Radiographic nonunion was uncommon and did not differ by plating. Time‐to‐Grade 2 osseous union was similar across plating strategies. Multivariate analysis demonstrated a significant association between nonunion and postoperative complications. Inter‐rater reliability for union grading was high. Conclusion: Microvascular mandibular reconstruction demonstrates comparable clinical and radiographic outcomes regardless of plate selection. Plate selection and CAD/CAM use should be driven by surgeon choice and reconstructive complexity. Level of Evidence: 3.

  • Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab

    by Angeline A. Truong, Savinnie Ho, Minna K. I. Apostolova, Rex H. Lee, Xin Wu, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, Ilya Likhterov, et al.

    Background: The prognostic implications of regional lymph node metastases at the initiation of immune checkpoint inhibitor (ICI) therapy in oral cavity squamous cell carcinoma (OCSCC) are not well defined. This study evaluated whether the presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with progression‐free or overall survival among patients with recurrent or metastatic (R/M) OCSCC. Methods: A retrospective cohort study was conducted at a tertiary academic medical center including patients with R/M OCSCC who initiated pembrolizumab between May 2016 and May 2022. Patients receiving fewer than three cycles were excluded. The presence of metastatic lymph node(s) at ICI initiation was analyzed as a dichotomous variable. The primary outcome was 6‐month progression‐free survival (PFS), and the secondary outcome was 2‐year overall survival (OS). Disease progression was determined using RECIST‐based radiographic criteria. Cox proportional hazards models adjusted for age, PD‐L1 status, presence of distant metastases, and receipt of concurrent systemic therapy. Results: Forty‐five patients met inclusion criteria; all received pembrolizumab for R/M disease. Twelve patients (27%) had metastatic cervical lymph nodes at ICI initiation. On univariate analysis, nodal metastasis was associated with poorer 6‐month PFS ( p = 0.024). After adjustment for age, PD‐L1 status, distant metastases, and concurrent systemic therapy, cervical nodal metastasis remained independently associated with inferior PFS (HR 5.12; 95% CI 1.30–20.2; p = 0.020). Conclusions: Presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with reduced 6‐month progression‐free survival, suggesting regional disease burden may predict limited ICI benefit in R/M OCSCC.

  • Open Access

    Economic Impact of a Deep Learning Algorithm for Automated Head and Neck Surgery Referral Triage

    by Stephanie Younan, Pearl Doan, Kevin Xin, Max L. Jiam, Patrick K. Ha, Katherine C. Wai, Nicole T. Jiam

    Objective: To quantify the comprehensive financial impact from implementing a deep learning algorithm for assistive patient triage within a high‐volume Head and Neck Surgical Oncology center operating under a fee‐for‐service framework. Methods: A prospective cost–benefit analysis compared a deep learning algorithm to standard manual triage on all incoming new patient referrals ( n = 214) in one fiscal quarter (FY24 Q3). Financial impact was calculated using a model aggregating two economic components: (1) annualized labor displacement savings, and (2) revenue impact of reallocating verified non‐indicated clinic slots to appropriate surgical candidates. Results: Automated head and neck referral triage demonstrated a net annual operating gain of $535,989, yielding a 14.9× return on investment. Directly measured labor savings ($236,788.80; 5.6× ROI) represent the conservative estimate; capacity value is modeled, contingent on slot reallocation. The AI‐assisted workflow displaces 1951.20 h of manual work (0.94 FTEs) annually per 6‐provider division processing 30 referrals/week, and up to 351,936 h (169.20 FTEs) per hospital system. Furthermore, the algorithm's superior accuracy identified 80 verified recoverable clinic slots per year for the division; reallocating these to appropriate candidates generated an additional $6.2 million in downstream revenue. Conclusion: The integration of a deep learning algorithm for Head and Neck Surgical Oncology referral triage delivers substantial financial benefits through the dual mechanisms of direct reduction of administrative labor and the strategic optimization of clinical capacity. By identifying non‐indicated referrals, the system allows for the reallocation of limited resources to patients requiring high‐acuity surgical oncological care, offering a scalable model for financial sustainability. Level of Evidence: NA.

  • Changes in Time to Diagnosis of HPV + Oropharyngeal Squamous Cell Carcinoma

    by Julia Howard, Shaheryar Asad, Danielle M. Gillard, Katherine C. Wai, Mary Jue Xu, Ilya Likhterov, Jonathan R. George, Ivan El‐Sayed, William R. Ryan, Patrick K. Ha, et al.

    Background: Timely referral to subspecialty care remains critical for expedited work up and treatment of HPV + oropharyngeal carcinoma (OPSCC). It is not known if there have been changes in time to diagnosis as the incidence of this disease rises. Methods: Retrospective cohort study of 312 patients treated for HPV + OPSCC at a tertiary referral clinic between 2013 and 2022. Results: There was a significant difference in time to diagnosis based on year of presentation ( p < 0.001). More patients presented with early‐stage disease (AJCC 7 Stage I or II) over time ( p = 0.002). Presenting symptom ( p = 0.021) and patient location ≥ 50 miles from our tertiary referral clinic ( p = 0.039) also affected time to diagnosis. Conclusions: Time to diagnosis of HPV + OPSCC changed based on year of presentation, and a higher proportion of patients presented with early‐stage disease in more recent years. This may reflect an increased public awareness of HPV + OPSCC and its symptoms.

  • Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer

    by Angeline A. Truong, Savinnie Ho, Rex H. Lee, Xin Wu, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, Ilya Likhterov, Mary Jue Xu, et al.

    Background: A minority of patients receiving immunotherapy for oropharyngeal head and neck squamous cell carcinoma benefit. Finding biomarkers that predict response to ICI is important for improving outcomes in these patients. In this study, we determine the relationship between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) oropharyngeal cancer on pembrolizumab. Methods: This study was a retrospective cohort study of patients with recurrent/metastatic OPSCC who were treated with pembrolizumab between May 2016 and May 2022 at a tertiary care academic center. The primary outcome was 6‐month progression‐free survival. The secondary outcome was 2‐year overall survival. NLR was treated as a continuous and dichotomous variable. Disease progression was determined using radiographic criteria adopted from the Response Evaluation Criteria in Solid Tumors. Results: Sixty‐four patients with OPSCC were included. The median pre‐treatment NLR was 5.1 (IQR 3.1–8.3). Thirty‐seven (58%) patients had distant metastases at the start of ICI. When treated as a continuous variable, higher pretreatment NLR was associated with poorer 6‐month PFS [HR 1.14 (1.03, 1.27), p = 0.016] and 2‐year OS [HR 1.21 (1.09, 1.35), p = 0.001] for patients on pembrolizumab. Subgroup analyzes on patients who were p16+ versus p16‐ revealed that NLR was only associated with poorer survival for p16+ patients [HR 1.16 (1.00, 1.33), p = 0.046 versus HR 1.11 (0.94, 1.31), p = 0.203, respectively]. Conclusion: Higher pretreatment NLR was associated with poorer 6‐month PFS and 2‐year OS in OPSCC patients treated with pembrolizumab. When stratified by p16 status, this association only remained significant among p16+ patients.

  • Open Access

    Pituitary metastasis as the first sign of distant spread in mandibular squamous cell carcinoma

    by Angeline A Truong, Jason Chan, Hyunseok Kang, Jia-Shu Chen, Manish Aghi, Patricia Loftus, Mary Jue Xu, Katherine C Wai

    To describe a rare case of pituitary metastasis arising from mandibular squamous cell carcinoma (SCC), in which pituitary-related symptoms represented the first clinical evidence of distant metastatic disease. Case report and targeted literature review. A patient with previously treated mandibular SCC presented with new-onset visual disturbance and endocrine dysfunction. Imaging, endocrine evaluation, and histopathologic confirmation were performed. Published reports of pituitary metastases from head and neck SCC were reviewed. Magnetic resonance imaging demonstrated an enhancing sellar mass with suprasellar extension and infundibular thickening concerning for metastatic disease. Endoscopic endonasal biopsy confirmed metastatic keratinizing SCC consistent with the primary mandibular tumor. No other distant metastases were identified on staging imaging. Visual field deficits and partial hypopituitarism were the sole presenting manifestations of metastatic spread. Pituitary metastasis from mandibular SCC is exceptionally rare and may present as the earliest sign of distant disease.

  • Open Access

    Timely Matters: Predictors of Delay in Oral Cavity Cancer Patients Across the Care Continuum

    by Nicholas Correia, Kennedy Johnson, Megan Durr, Barbara A. Grimes, Ann A. Lazar, Urmimala Sarkar, Patrick K. Ha, Laura Chen, Katherine C. Wai, Ilya Likhterov, et al.

    Objective: Limited literature focuses on delays in accessing head and neck cancer (HNC) care across the entire care continuum. This study aims to describe the time to care from symptom onset to treatment completion and identify predictors of delays for oral cavity cancer patients. Methods: We reviewed patients with oral cavity squamous cell carcinoma (OCSCC) treated with curative surgery followed by adjuvant treatment at a tertiary center. Delays were defined per published thresholds for: time to treatment initiation (TTI, diagnosis to surgery), time to adjuvant treatment (stratified by whether adjuvant treatment was at the same or different facility as surgery), and total treatment package time. We also measured symptom duration, reported median times, and used logistic regression to assess predictors of delay. Results: Among 93 patients, median (IQR) symptom duration was 17.4 weeks (IQR: 6.8–42.8); TTI 6.9 weeks (IQR: 4.4–10.4); time to adjuvant radiation 8.4 weeks (IQR: 7.4–9.3) at the same institution as surgery was performed and 9.3 weeks (IQR: 7.4–14) at a different facility; and total treatment package time 15.4 weeks (IQR: 12.6–20) for surgery and adjuvant radiation, and 16.3 weeks (IQR: 15–18.6) for surgery and adjuvant chemoradiation. 73% of patients experienced delays in reaching a healthcare facility, 39% in TTI, 89% in starting adjuvant treatment, and 64%–81% in total treatment time. In univariate analyses, late‐stage disease, residing in a community with higher social vulnerability index (SVI), longer time from surgery to pathology report, need for free flap, and social worker interaction were associated with higher odds of delay in any care interval following diagnosis. Higher SVI was associated with delays in multivariate analyses. Conclusion: HNC patients experience delays during all phases of cancer care. Interventions and future research need to address social determinants of health and health system factors that contribute to multifactorial delays across the care continuum.


  • Perineural Invasion and Survival in Pembrolizumab‐Treated Head and Neck Squamous Cell Carcinoma

    by Angeline A. Truong, Savinnie Ho, Rex H. Lee, Xin Wu, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, Ilya Likhterov, Mary Jue Xu, et al.

    Objective: To determine the relationship between perineural invasion and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on pembrolizumab. Methods: This study was a retrospective, observational study performed at a tertiary care academic center. Participants included patients with oral cavity, oropharynx, hypopharynx, and laryngeal head and neck squamous cell carcinoma who began pembrolizumab treatment at UCSF between May 2016 and May 2022. The primary outcome was 6‐month progression‐free survival and 6‐month time‐to‐progression (TTP). The secondary outcome was 2‐year overall survival. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors. Results: One hundred and thirty‐three patients with HNSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. Forty (30%) patients had perineural invasion. On univariate analysis, patients with perineural invasion were more likely to have worse 6‐month PFS ( p = 0.011). After controlling for number of metastatic organs, receipt of concurrent systemic therapy, age, and PDL‐1 status, presence of perineural invasion was associated with worse 6‐month PFS [HR 3.33 (1.32, 8.41), p = 0.011] and 6‐month time to progression (TTP) [HR 2.14 (1.09, 7.38), p = 0.032], but was not significantly associated with 2‐year OS [HR 1.35 (0.57, 3.19), p = 0.498]. Conclusion: Presence of perineural invasion is associated with poorer 6‐month progression‐free survival on ICI in patients with HNSCC. Future studies should further explore how perineural invasion may alter response to immunotherapy. Level of Evidence: 3